A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx™) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer

Clinical Lung Cancer

Volumn 5, Issue 2, 2003, Pages 107-112

  Leighl, Natasha B ^a   Burkes, Ronald L ^a   Dancey, Janet E ^a   Lopez, Pedro G ^b   Higgins, Brian P ^c   Walde, P L David ^d   Rudinskas, Leona C ^e   Rahim, Yasmin H ^f   Rodgers, Angela ^g   Pond, Gregory R ^a   Shepherd, Frances A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Northeastern Ontario Regional Cancer Centre   (Canada)

^c CREDIT VALLEY HOSPITAL   (Canada)

^d Department of Medical Oncology   (Canada)

^e HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^f TORONTO EAST GENERAL HOSPITAL   (Canada)

^g INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Fatigue; Hand foot syndrome; Neutropenia; Radiation therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; LIPOSOME; PLATINUM DERIVATIVE; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RASH; SEPSIS; THROMBOCYTOPENIA; VOMITING;

EID: 20244365597     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.024     Document Type: Article

References (23)

1. Tyczynski JE, Bray F, Parkin DM. Lung Cancer in Europe. European Network of Cancer Registries Cancer Fact Sheets. Vol. 1, March 2002.
2. American Cancer Society. Cancer Facts and Figures 2002. New York: National Media Office, 2002.
3. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61:584-589.
4. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14:2785-2790.
5. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT- 11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225-1229.
6. Kelley MJ, Linnoila RI, Avis IL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112:256-261.
7. Lynch TJ Jr, Lambert JM, Coral F, et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15:723-734.
8. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002; 13:539-545.
9. Arriagada R, Kramar A, Le Chevalier T, et al. Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. J Clin Oncol 1992; 10:447-451.
10. Postmus PE, Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol 2001; 28:48-52.
11. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
12. Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987; 71:941-944.
13. Doxil™ Investigator's Brochure. Menlo Park, CA: SEQUUS Pharmaceuticals, Inc., 1996.
14. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445-2451.
15. Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin bleomycin, and vincristine. Cancer Invest 2001; 19:573-580.
16. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
17. Ranson JH, Lawrence LR, Localio SA. Colomyotomy. A new approach to surgery for colonic diverticular disease. Am J Surg 1972; 123:185-191.
18. Samantas E, Kalofonos H, Linardou H, et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann Oncol 2000; 11:1395-1397.
19. National Cancer Institute of Canada Clinical Trials Group. Expanded Common Toxicity Criteria. Toronto: NCIC, 1994.
20. Cancer Care Ontario Practice Guidelines Initiative. Second line chemotherapy for relapsed small cell lung cancer. Evidence-summary-in-progress. Available at: http://www.ccopebc.ca.
21. O'Bryan RM, Crowley JJ, Kim PN, et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990; 65:856-860.
22. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
23. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer; Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003; 21:1550-1555.